Product Description
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Herantis Pharma
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Germany, Poland
Active Clinical Trial Count: 2
Highest Development Phases
Phase 2: Parkinson's Disease
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
ASK-PD5-CS201 | P2 |
Unknown Status |
Parkinson's Disease |
2027-12-01 |
|
Long-Term Follow-up Safety After DDS Implantation with/without CDNF Infusions | P2 |
Active, not recruiting |
Parkinson's Disease |
2023-12-30 |